Clinical Trial Results: A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia [Phase 2]

View source ↗

Summary

Phase II dose-escalation study evaluating the pharmacokinetics of eltrombopag in pediatric patients with severe or recurrent aplastic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Aplastic Anemia | Phase 2 | Status: COMPLETED | Results posted: 2026-08-10